PhaseRx, Inc., a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, has filed for protection under Chapter 11 of the Bankruptcy Code in Delaware. The company states it intends to continue normal operations while it works with Cowen & Co. to review alternatives, including a strategic merger or the licensing, sale or divestiture of its technologies. More information about the company is available at www.phaserx.com.
The US Trustee has scheduled a meeting to form a committee of unsecured creditors to be held on December 20, 2017 at 11:00 a.m. at the US Trustee’s office in Wilmington, Delaware.
The weather forecast in Delaware that day? Partly cloudy with a low of 28 and a high of 42 degrees.
Bring a coat.